SecBot SecBot
SC 13G ·Filed Nov 5, 2026

TARS

Tarsus Pharmaceuticals, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed11d 13h ago SEC0000315066-26-002878
Passive investor 5%+ stake
Actionable Insight • Neutral

Fidelity's new 6.4% passive stake signals institutional confidence in Tarsus' commercial trajectory following strong XDEMVY sales. Monitor for any future 13G amendments showing position increases or a potential 13D conversion if the holder engages actively.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$67.52
T+0 close · Nov 5, 2026 · via day close
Latest settled
+13.88%
T+5 · $76.89
Vs SPY
+10.59%
α at T+5
Next horizon
T+20
in 17d
  1. T+0 · Nov 5 $67.52entry
  2. T+1 · 11d ago +1.60%α +1.29% · $68.60
  3. T+5 · 5d ago +13.88%α +10.59% · $76.89
  4. T+7 · todayOpen
  5. T+20 · in 17d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

FMR LLC (Fidelity) filed a Schedule 13G disclosing a 6.4% passive stake in Tarsus Pharmaceuticals as of September 30, 2026, representing 3,143,158.20 shares. This is a new filing (not an amendment) and certifies passive intent with no control or influence purpose. The disclosure follows Tarsus' Q3 2026 earnings report showing strong XDEMVY revenue growth of ~64% YoY to $194.6 million.

Key Financial Metrics

Stake
6.4%
Investor
FMR LLC
Investor Type
mutual fund

Key Facts

  • FMR LLC (Fidelity) filed a new Schedule 13G disclosing beneficial ownership of 3,143,158.20 shares of Tarsus Pharmaceuticals common stock
  • Stake represents 6.4% of shares outstanding as of September 30, 2026
  • Filing certifies passive intent under Rule 13d-1(b) with no purpose of changing or influencing control
  • Filing date is November 5, 2026, with ownership measured as of September 30, 2026
  • No prior SC 13G filing by FMR LLC for Tarsus was found in the cross-filing context; this appears to be an initial filing

Financial Impact

6.4% stake valued at approximately $230 million based on $3.6B market cap

ownership_percentage

Risk Factors

  • Passive filing precludes activist intent; no control or influence campaign is signaled
  • Stake size (6.4%) is moderate and does not indicate an imminent takeover or strategic transaction

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
94% bullish (16 analysts)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G Filing (Primary)0000315066-26-002878
Document: 0000315066-26-002878-index-headers.html0000315066-26-002878
Document: 0000315066-26-002878-index.html0000315066-26-002878
Document: 0000315066-26-002878.txt0000315066-26-002878

Track record

21 reports on TARS

Performance horizon

5 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +27.36% at T+20 after the Aug 6, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 13, 20263d ago 144 Neutral 2/10 Entry $76.56 Now $78.68 +2.78% settles Nov 23
  2. Nov 5, 202611d ago 3 Neutral 2/10 Entry $68.60 to $80.28 Now $78.68 +14.69% ▲ +17.03% +14.43% vs SPY
  3. Nov 5, 202611d ago SC 13G Neutral 3/10 Viewing Entry $67.52 to $76.89 Now $78.68 +16.53% ▲ +13.88% +10.59% vs SPY
  4. Nov 3, 202613d ago 8-K Neutral 5/10 No price data
  5. Nov 3, 202613d ago Press Release Neutral 5/10 Entry $69.07 to $76.76 Now $78.68 +13.91% ▲ +11.13% +12.05% vs SPY
  6. Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $69.50 to $70.03 Now $78.68 +13.21% ▲ +0.76% +0.91% vs SPY
  7. Oct 13, 20264w ago S-3ASR Neutral 4/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  8. Oct 13, 20264w ago S-3ASR Neutral 3/10 Entry $72.29 to $70.50 Now $78.68 +8.84% ▼ −2.48% −2.93% vs SPY
  9. Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $81.12 to $79.03 Now $78.68 −3.01% ▼ −2.58% −3.21% vs SPY
  10. Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $90.78 to $79.95 Now $78.68 −13.33% ▼ −11.93% −10.72% vs SPY
Showing 10 of 21

US Market Status

Market Closed · Opens in 6h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 5, 2026